178 related articles for article (PubMed ID: 33588674)
1. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine.
Huang H; Schmerold L; Dembek C; Fan Q; Dieyi C; Williams GR; Loebel A
J Med Econ; 2021; 24(1):352-362. PubMed ID: 33588674
[TBL] [Abstract][Full Text] [Related]
2. Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder.
Laliberté F; Zanardo E; MacKnight SD; Urosevic A; Wade SW; Parikh M
J Manag Care Spec Pharm; 2024 Feb; 30(2):118-128. PubMed ID: 38308622
[TBL] [Abstract][Full Text] [Related]
3. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
[TBL] [Abstract][Full Text] [Related]
4. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
5. Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
Tohen M; Ng-Mak D; Rajagopalan K; Halpern R; Chuang CC; Loebel A
Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28590601
[TBL] [Abstract][Full Text] [Related]
6. Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data.
Niu X; Veeranki P; Dennen S; Dembek C; Laubmeier K; Liu Y; Williams GR; Loebel A
Curr Med Res Opin; 2021 May; 37(5):839-846. PubMed ID: 33682547
[TBL] [Abstract][Full Text] [Related]
7. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
[TBL] [Abstract][Full Text] [Related]
10. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
13. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
14. Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.
Niu X; Dennen S; Dembek C; Laubmeier K; Liu Y; Veeranki P; Tocco M; Williams GR
Curr Ther Res Clin Exp; 2021; 94():100629. PubMed ID: 34306269
[No Abstract] [Full Text] [Related]
15. The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis.
Niu X; Dembek C; Fan Q; Mao Y; Divino V; Burch S; Tocco M
J Med Econ; 2022; 25(1):152-159. PubMed ID: 35037813
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.
Newcomer JW; Ng-Mak D; Rajagopalan K; Loebel A
BMC Health Serv Res; 2018 Apr; 18(1):243. PubMed ID: 29618351
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and impact of antipsychotic discontinuation among commercially-insured patients with bipolar disorder.
Khandker R; Chekani F; Limone B; Riehle E
J Med Econ; 2023; 26(1):878-885. PubMed ID: 37455610
[TBL] [Abstract][Full Text] [Related]
18. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
19. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
Jiang Y; Ni W
J Manag Care Spec Pharm; 2015 Sep; 21(9):780-92. PubMed ID: 26308225
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]